Delhi High Court: Phonetic Similarity between Boat & Boult Can Cause Confusion Online || SC: Recording Reasons Is Mandatory For Searches without A Warrant under Special Laws || SC Dismissed MP Police Plea against Quashing FIR Alleging Marital Cruelty against MLA Umang Singhar || SC Held Financial Bids in Public Tenders Cannot Be Altered Post-Opening To Protect Process Sanctity || SC: Defendant Cannot File a Counter-Claim against a Co-Defendant under Order VIII Rule 6-A CPC || Supreme Court Ruled That Barring Non-Muslims from Creating Waqfs Is Not Prima Facie Arbitrary || SC Rejected Writ Petition Seeking Review of Judgment Upholding WB Madrasah Service Commission Act || SC Grants Interim Bail to Mahesh Raut on Medical Grounds in Bhima Koregaon Case || SC: Non-Production of Contraband Not Fatal If Seizure and Sample-Drawing Follow S.52A of NDPS Act || Supreme Court Takes Suo Motu Cognizance of Industrial Pollution in Rajasthan's Jojari River

Merck Sharp & Dohme Corporation & Anr. v. Glenmark Pharmaceuticals Ltd. - (High Court of Delhi) (07 Oct 2015)

Delhi High Court rules in favour of Merck for its diabetes drug

Intellectual Property Rights

The Delhi High Court restrained Glenmark from selling any drug containing Sitagliptin or its derivate. Sitagliptin is the active ingredient used in ‘Januvia’, Merck’s once-daily pill used to lower blood sugar levels in people with Type II diabetes. It had claimed that Glenmark had infringed its patent in the specific chemical. The court dismissed contentions that Glenmark’s product, ‘Zita’, was different from Merck’s product.

Relevant : Read the decision in Merck Sharp & Dohme Corporation v. Glenmark Pharmaceuticals Ltd.

Tags : GLENMARK MERCK PATENT DIABETES

Share :